Bacillus subtilis: strains and products
How to distinguish B. subtilis strains, live cultures and heat-treated BG01-4.
Key points
- BS50, MB40, R0179 and CU1 are different strains of Bacillus subtilis, and a blend may contain other cultures as well. When choosing a product, check the exact code and composition: a result for one strain does not describe the entire blend. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] See the evidence 1
- For a live culture, the number of colony-forming units through the end of shelf life and storage conditions on the package are important. A higher number alone does not mean a greater effect. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] See the evidence 1
- In a study of heat-treated BG01-4 in adults with long-standing bowel complaints, the constipation symptom score fell by 33% versus 15% with placebo over four weeks. Certainty is very low; the CFU count reported in the article is not defined as a dose of live bacteria. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] See the evidence 1 2
Practical guide
Check the findings and their applicability to your situation.
A study result applies to the specific strain or product and its dose.
Key points
Why these conclusions
Strains and products
The live strains BS50, MB40, R0179 and CU1 were studied separately. BG01-4 was used after heating; the article does not specify whether the reported CFU count relates to before or after heating. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]
In adults with long-standing bowel complaints without IBS, one 1 g sachet of BG01-4 daily was compared with placebo for four weeks. In the main analysis, the constipation symptom score decreased by 33% versus 15%; certainty is very low — 1 out of 4. [1]
Food strains of B. subtilis have been isolated from natto and other fermented foods. Their presence does not establish the results found for BS50 or MB40; the number of live bacteria in a typical serving was not determined in these studies. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]
Information from the source
| Name | Description | Sources |
|---|---|---|
| Live strains in capsules | BS50, MB40, R0179 and CU1 are different strains with their own studies. On the label, the strain code, CFU count through the end of shelf life and storage conditions matter. A higher CFU count alone does not mean a greater effect. | [11] [2] [7] [10] [5] |
| BG01-4 after heating | The study used a sachet containing 1 g of powder after heat treatment. The article also reports 5 billion CFU, but does not explain whether this figure refers to the state before or after heating. It is therefore not presented here as a dose of live bacteria. | [1] |
| Food cultures | Natto and other fermented foods have their own food strains. Their presence in a product does not establish an effect of BS50 or MB40. Preparation can change the number of live bacteria; in a natto study, boiling reduced it. | [3] [8] [9] [4] [6] |
Information from the source
The table lists foods from which B. subtilis was isolated; it is not a ranking by bacterial count. The number of live bacteria in a typical serving was not determined in these studies. For soy foods, the form of the sample from the study is shown. There is no general daily dietary requirement or single tolerable upper level for B. subtilis; doses in trials apply to specific strains. [3] [8] [9] [4]
Presence in foods
| Name | Form | Description | Note | Sources |
|---|---|---|---|---|
| Natto — Japan | Fermented soybeans | Food strains of B. subtilis were isolated from this product. | Food strains of B. subtilis were isolated from this product. | [3] |
| Kinema — Nepal | Sun-dried blocks of fermented soybeans | Food strains of B. subtilis were isolated from this product. | Food strains of B. subtilis were isolated from this product. | [3] |
| Cheonggukjang — Korea | Fermented soybean paste | Food strains of B. subtilis were isolated from this product. | Food strains of B. subtilis were isolated from this product. | [3] |
| Thua nao — Thailand | Sun-dried soybean sheets | Food strains of B. subtilis were isolated from this product. | Food strains of B. subtilis were isolated from this product. | [3] [8] |
| Pè pok — Myanmar | Semi-dried blocks of fermented soybeans | Food strains of B. subtilis were isolated from this product. | Food strains of B. subtilis were isolated from this product. | [3] |
| Mak thua nao — Laos | Fermented soybean paste | Food strains of B. subtilis were isolated from this product. | Food strains of B. subtilis were isolated from this product. | [3] |
| Soumbala — Burkina Faso | Condiment made from fermented Parkia biglobosa seeds | Food strains of B. subtilis were isolated from this product. | Food strains of B. subtilis were isolated from this product. | [9] |
| Bikalga — Burkina Faso | Condiment made from fermented Hibiscus sabdariffa seeds | Food strains of B. subtilis were isolated from this product. | Food strains of B. subtilis were isolated from this product. | [4] |
Information from the source
In a study of 5 billion CFU of MB40 daily, adverse events were reported in both groups. Those possibly related to the supplement included constipation, abdominal discomfort, diarrhea, gas and dry mouth; they had resolved by the end of the study. In a separate tolerability study of 10 billion CFU of MB40 daily, one participant experienced vomiting and chills, which the authors considered probably related to intake. They resolved within 31 hours. In the R0179 study, one participant in the 10 billion CFU group discontinued after itching and skin redness; a causal relationship was not established. In people with severe illness, weakened immunity or a central venous catheter, live probiotics require individual medical assessment because of the risk of infection. The FDA issued a separate warning for hospitalized preterm infants. This information applies to probiotics in general, not to an established infection rate for each B. subtilis strain. [2] [5] [12] [7] [13]
In the main analysis, the authors reported a 33% reduction in constipation symptoms on the questionnaire with BG01-4 and a 15% reduction with placebo.
| Parameter | Data |
|---|---|
| Result | In the main analysis, the authors reported a 33% reduction in constipation symptoms on the questionnaire with BG01-4 and a 15% reduction with placebo. |
| Participants | Adults aged 18–75 with self-reported long-standing bowel complaints; IBS was excluded. A total of 80 people were allocated under the study design (42 and 38), and 67 were included in the analysis (34 and 33). |
| Form | BG01-4: heat-treated bacterial powder in a sachet with maltodextrin |
| Dose | One 1 g sachet daily; contents added to 250 mL of water, juice or food |
| Dose basis | One 1 g sachet daily; contents added to 250 mL of water, juice or food |
| Comparison | Placebo sachet with maltodextrin |
| Duration | 4 weeks |
| Certainty | 1/4: One preliminary study; 13 of 80 allocated participants did not complete the protocol. The main figure and a supplementary analysis table report different magnitudes of improvement in constipation. The text also contains errors in group sizes. These discrepancies explain the very low certainty. |
| Body of evidence | 1 publication described |
| Sources | [1] |
Sources
- Bacillus Subtilis (BG01-4(TM)) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial. https://pubmed.ncbi.nlm.nih.gov/37960143/
- A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating. https://pubmed.ncbi.nlm.nih.gov/31719214/
- Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0141369
- Co-production of surfactin and a novel bacteriocin by Bacillus subtilis subsp. subtilis H4 isolated from Bikalga, an African alkaline Hibiscus sabdariffa seed fermented condiment. https://www.sciencedirect.com/science/article/pii/S0168160513000421
- Probiotics — Health Professional Fact Sheet (NIH ODS). https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/
- Treatment of natto, a fermented soybean preparation, to prevent excessive plasma vitamin K concentrations in patients taking warfarin. https://pubmed.ncbi.nlm.nih.gov/17190098/
- Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults. https://pubmed.ncbi.nlm.nih.gov/25062611/
- Characterization of Bacillus subtilis strains in Thua nao, a traditional fermented soybean food in northern Thailand. https://doi.org/10.1111/j.1472-765X.2006.01966.x
- Genotyping of starter cultures of Bacillus subtilis and Bacillus pumilus for fermentation of African locust bean (Parkia biglobosa) to produce Soumbala. https://pubmed.ncbi.nlm.nih.gov/14698101/
- Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. https://pubmed.ncbi.nlm.nih.gov/26640504/
- The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/36269141/
- FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants. https://www.fda.gov/news-events/press-announcements/fda-raises-concerns-about-probiotic-products-sold-use-hospitalized-preterm-infants
- Safety Assessment of Bacillus subtilis MB40 for Use in Foods and Dietary Supplements. https://pubmed.ncbi.nlm.nih.gov/33668992/
Methodology: Subpages evidence-led supplement pipeline v1